CONMED Corp CNMD revenue by segment, product and geography
In its fiscal year ending 2025-12-31, CONMED Corp reported revenue across 2 products and services; the largest, General Surgery, was $800M, 58.2% of the filed sum (+4.9% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- General Surgery$800M58.2%+4.9% yoy
- Orthopedic Surgery$575M41.8%+5.6% yoy
Members sum to the consolidated $1.37B for this period.
- United States$775M56.3%+3.5% yoy
- EMEA$265M19.3%+8.9% yoy
- Asia Pacific$209M15.2%+7.2% yoy
- Americasexcludingthe United States$127M9.2%+4.7% yoy
Members sum to the consolidated $1.37B for this period.
- General Surgery$191M55.7%-5.2% yoy
- Orthopedic Surgery$152M44.3%+8.2% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.